
NOW FDA-APPROVED



FOR EMERGENCY TREATMENT OF OPIOID OVERDOSE

Please see Indication and Important Safety Information below.



√ Ready-to-use

✓ Needle-free

Full Prescribing Information 🖟

Quick Start Guide

Group Purchasers

Press Materials 2

* NARCAN® NASAL SPRAY

Commercial Availability

NARCAN® (naloxone HCl) Nasal Spray 4 mg is scheduled to become commercially available early 2016.

For more information on NARCAN® Nasal Spray call 844-4-NARCAN (844-462-7226) or email customerservice@adaptpharma.com

Indications and Important Safety Information

INDICATIONS

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.

NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal and acute withdrawal syndrome. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

See Instructions for Use and full prescribing information in the use of this product.

To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 🗗.

Privacy Statement | Terms of Use | Contact Us | Media 🗹

© 2015 ADAPT Pharma, Inc. NARCAN® is a registered trademark licensed to ADAPT Pharma Operations Limited.

NAR4-08-15 ADAPT Pharma, Inc. Radnor, PA






If this is an emergency, call 911. This site is intended for US residents.

NOW FDA-APPROVED



FOR EMERGENCY TREATMENT OF OPIOID OVERDOSE

Please see Indication and Important Safety Information below.



√ Ready-to-use

✓ Needle-free



Full Prescribing Information 🖹

Quick Start Guide A

Group Purchasers

Press Materials 2

Group Purchasers

NARCAN® Nasal Spray will be available to group purchasers, such as law enforcement, firefighters, first responders, departments of health, educational facilities and community based organizations.

For information, pre-ordering or purchasing NARCAN® Nasal Spray (NDC: 69547-353-02) upon availability, contact 844-4-NARCAN (844-462-7226) or email customerservice@adaptpharma.com

Indications and Important Safety Information

INDICATIONS

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.

NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

<u>Precipitation of Severe Opioid Withdrawal</u>: Use in patients who are opioid dependent may precipitate opioid withdrawal and acute withdrawal syndrome. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

See Instructions for Use and full prescribing information in the use of this product.

To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ☑*.

Privacy Statement | Terms of Use | Contact Us | Media 🗹

© 2015 ADAPT Pharma, Inc. NARCAN® is a registered trademark licensed to ADAPT Pharma Operations Limited.

NAR4-08-15 ADAPT Pharma, Inc. Radnor, PA





If this is an emergency, call 911. This site is intended for US residents **NOW FDA-APPROVED** * NARCAN (naloxone HCI) **NASAL SPRAY 4mg** FOR EMERGENCY TREATMENT OF OPIOID OVERDOSE Please see Indication and Important Safety Information 4 mg nasal dose in single spray

✓ Ready-to-use



Full Prescribing Information Quick Start Guide Group Purchasers

Press Materials @

Adapt Pharma, Inc. respects the privacy of visitors to our websites, and as a result, we have developed this Online Privacy Statement. We may update this Statement from time to time.

Scope
This Privacy Statement applies only to the operation of websites that directly link to this statement when you click on "Privacy Statement" in the

website footer.

CONSENT TO PROCESSING IN THE UNITED STATES AND ELSEWHERE. This site is owned and operated by Adapt Pherma in the United States, but the Information you provide may be excessible to our affiliates, vendors and supplies in other countries. By using this site, you consent to be collection, strongs and processing of your information in the United States and in any country to which we may transfer your information in the course of our business operations.

as a return visitor to sur site. We use cookies without directly identifiable personal information to bring you content and features (kely to be of interest to you, bedo on your previous activities on our site.)

How We Use Your Information

Whe log, IP. Address and other Information returning or quartery collected by an inebservers in connection with year visit to this verballe will be used to better understand your needs and openend user fulfile patterns, and to improve our verballers and services. We may enhance or neepy this information with other data we may have been during a similar or the services and openend user fulfile patterns, and to improve our verballers and services. We may enhance or neepy this information with other data we may have been days as well as the similar from thirty parties for the same purposes. We retain IP addresses and also may use you'll pedderes to prevail the other and the services of the same purposes. We retain IP addresses and also may use you'll pedderes to prevail the other and the pedderes and the information contained in them.

We Becomes, One Pharman or its appearing, contraders, and business partners. Adapt Pharma metals all rights to these databases and the information contained in them.

We Becomes, One wheelers may use we'b becames (prometimes called single-poles (IPS) to generate web log information. Conteins Out websiness and detect whether you have cookes anyour computer. It is possible that a cookie may contain information that could be deemed identifiated. We may use the data we obtain through the use of cookes to touch anyour advantage of the personal conteins that could be deemed identifiated. We may use the data we obtain through the use of cookes and formation conteins out through the use of cookes for our business purposes, including operation of our site, as well as research and product analyses to help us better market or products. This includes and to made the seconds and information and out our admitted analyses to help us better market or products.

Sharing Your Information
We may share be information we collect through this website with our employees, agents, contractors or partners in connection with services that these includuals or criticise perform for or with us. Those agents, contractors or partners are readred from using these data in any way often than to perform these services. Adapt Planma expects our employees and performent in entainist in the trust placed in us by those with opprovide us with information by using reasonable deministrative, technical and physical safeguards. Adapt Planma reserves the right to share information to present on the present of the p

Social Mail Plugins
Our websites may use social media plugins to enable you to easily share information with others. When you visit our websites, the operator of the social media plugin that is on our websites, and pace a cookie on your computer, enabling that operator to recognize individuals on their website who have previously visited our after. If you are logged into the social media vebsite white browsets could media vebsite or the received integrity in the plugins may allow that social media vebsite to receive directly integritable information boot you that shows you have visited our vebsite. Social media vebsite, plugins also solve the social media vebsite to receive directly engines also solve the social media vebsite. Adapt Pharma does not control any of the contest from social media vebsite. Adapt Pharma does not control any of the contest from social media vebsite. After pharma does not control any of the contest from social media vebsites, you should refer to hose sites phacy and data sharing statements.

currently response to traces arginar. Children
This sale is not apply to the designed to attract individuals under the age of 18.

If you have any questions or comments about this Privary Statement, please contact us by writing to:
Adapt Privary Thomas, Inc.

100 Mateoriford Road

Indications and Important Safety Information

NARCANP (naloxone hydrochloride) Nasal Spray is an opicid antagonist indicated for the emergency treatment of known or suspected opicid overdose, as manifested by respiratory and/or central nervous system depression.

NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Reserved to such assume the pattern and the pa

Bisk of Limited Efficacy with Partial Agonists or Mond Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists similar partial p

Precipitation of Severe Opioid Withdrawal: Use in patients who are opioid dependent may precipitate opioid withdrawal and soute withdrawal syndrome. In neonates, opioid withdrawal may be life-threstening if not recognized and properly treated. Monitor for development of opioid withdrawal.

seressions no studie and orange. An extraction of the contraction of t

The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

See Instructions for Use and full prescribing information in the use of this product.

To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-INARCAN (1-844-482-7228) or FDA at 1-840-FDA-1088 or www.fox.gov/imedwatch [2].

Privacy Statement | Terms of Use | Contact Us | Media 2

© 2015 ADAPT Pharma, Inc. NARCAN^o is a registered trademark licensed to ADAPT Pharma Operations Limited. NAR4-08-15 ADAPT Pharms, Inc. Radnor, PA






NOW FDA-APPROVED



FOR EMERGENCY TREATMENT OF OPIOID OVERDOSE

Please see Indication and Important Safety Information below.



✓ Ready-to-use

√ Needle-free



Full Prescribing Information 🖟

Quick Start Guide

Group Purchasers

Press Materials 17

Terms of Use

By using this site you acknowledge that Adapt Pharma, Inc. is providing the material for informational purposes only and that neither Adapt Pharma nor their agents, affiliates, partners, or licensors are providing the materials to you for the purposes of giving you medical advice. You should not rely on the materials in deciding on a treatment plan, drug usage, or any other medical advice regarding the materials, and Adapt Pharma and their licensors strongly urge that you consult with a physician in connection with any and all treatment options that may be available to you.

By using this website, you accept the information, products, and services provided herein "as is." Adapt Pharma makes no express or implied warranty regarding the accuracy, content, completeness, reliability, or legality of information contained within this website, including, without limitation, the warranties of merchantability, fitness for a particular purpose, and non-infringement of proprietary rights.

In no event shall Adapt Pharma, or its agents, affiliates, partners, or licensors be liable for any direct, special, indirect, incidental or consequential damages or any damages whatsoever resulting from loss related to the use of our websites, whether in an action of contract, breach of warranty, negligence, or other tortious action arising out of or in connection with the use of the materials contained on this site.

Indications and Important Safety Information

INDICATIONS

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present. NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

<u>Precipitation of Severe Opioid Withdrawal</u>: Use in patients who are opioid dependent may precipitate opioid withdrawal and acute withdrawal syndrome. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

See Instructions for Use and full prescribing information in the use of this product.

To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or yown fda gov/medwatch [7]

Privacy Statement | Terms of Use | Contact Us | Media 🗹

© 2015 ADAPT Pharma, Inc. NARCAN® is a registered trademark licensed to ADAPT Pharma Operations Limited. NAR4-08-15 ADAPT Pharma, Inc. Radnor, PA






If this is an emergency, call 911. This site is intended for US residents.

NOW FDA-APPROVED



FOR EMERGENCY TREATMENT OF OPIOID OVERDOSE

Please see Indication and Important Safety Information below.



√ Ready-to-use

√ Needle-free



Full Prescribing Information 🗷

Quick Start Guide

Group Purchasers

Press Materials 2

Contact Us

If you have a medical emergency, you should immediately call 911 or your local emergency services number.

Adapt Pharma, Inc. US Headquarters 100 Matsonford Road Building 4, Suite 201 Radnor, PA 19087

Tel: +1-844-ADAPT-11 (1-844-232-7811)
Email: info@adaptpharma.com
www.adaptpharma.com

Indications and Important Safety Information

INDICATIONS

NARCAN® (naloxone hydrochloride) Nasal Spray is an opioid antagonist indicated for the emergency treatment of known or suspected opioid overdose, as manifested by respiratory and/or central nervous system depression.

NARCAN® Nasal Spray is intended for immediate administration as emergency therapy in settings where opioids may be present.

NARCAN® Nasal Spray is not a substitute for emergency medical care.

IMPORTANT SAFETY INFORMATION

NARCAN® Nasal Spray is contraindicated in patients known to be hypersensitive to naloxone hydrochloride.

Seek emergency medical assistance immediately after initial use, keeping the patient under continued surveillance.

Risk of Recurrent Respiratory and CNS Depression: Due to the duration of action of naloxone relative to the opioid, keep the patient under continued surveillance and administer repeat doses of naloxone using a new nasal spray with each dose, as necessary, while awaiting emergency medical assistance.

Risk of Limited Efficacy with Partial Agonists or Mixed Agonists/Antagonists: Reversal of respiratory depression caused by partial agonists or mixed agonists/antagonists, such as buprenorphine and pentazocine, may be incomplete. Larger or repeat doses may be required.

<u>Precipitation of Severe Opioid Withdrawal</u>: Use in patients who are opioid dependent may precipitate opioid withdrawal and acute withdrawal syndrome. In neonates, opioid withdrawal may be life-threatening if not recognized and properly treated. Monitor for development of opioid withdrawal.

Risk of Cardiovascular (CV) Effects: Abrupt postoperative reversal of opioid depression may result in adverse CV effects. These events have primarily occurred in patients who had pre-existing CV disorders or received other drugs that may have similar adverse CV effects. Monitor these patients closely in an appropriate healthcare setting after use of naloxone hydrochloride.

The following adverse reactions were observed in a NARCAN Nasal Spray clinical study: increased blood pressure, musculoskeletal pain, headache, nasal dryness, nasal edema, nasal congestion, and nasal inflammation.

See Instructions for Use and full prescribing information in the use of this product

To report SUSPECTED ADVERSE REACTIONS, contact Adapt Pharma, Inc. at 1-844-4NARCAN (1-844-462-7226) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch ☑*.

Privacy Statement | Terms of Use | Contact Us | Media 🗷

© 2015 ADAPT Pharma, Inc. NARCAN® is a registered trademark licensed to ADAPT Pharma Operations Limited.

NAR4-08-15 ADAPT Pharma, Inc. Radnor, PA



